RECURRENT MANTLE CELL LYMPHOMA
Clinical trials for RECURRENT MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-phase trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatment. The main goal was to find the safest dose and identify side effects. Researchers also looked at whet…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:51 UTC
-
Can nivolumab rescue patients when CAR T-Cell therapy fails?
Disease control CompletedThis study tested the drug nivolumab in 20 people with blood cancers (like lymphoma, leukemia, or myeloma) that came back or didn't respond after CAR T-cell therapy. Nivolumab is an immunotherapy that helps the body's immune system attack cancer cells. The main goal was to see ho…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 06:49 UTC
-
Triple attack on lymphoma: freeze, vaccinate, and boost immunity
Disease control CompletedThis study tested a new combination treatment for people with non-Hodgkin lymphoma that had come back. The approach used three steps: first, freezing the tumor to kill cancer cells; second, injecting a personalized vaccine made from the patient's own immune cells; and third, givi…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:50 UTC